1.Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ: A clinico-pathological study of subtypes in Parkinson’s disease. Brain: a journal of neurology 2009, 132(Pt 11):2947–2957.
2.DeWitt DA, Richey PL, Praprotnik D, Silver J, Perry G: Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases. Brain research 1994, 656(1):205–209.
3.Carulli D, Laabs T, Geller HM, Fawcett JW: Chondroitin sulfate proteoglycans in neural development and regeneration. Current opinion in neurobiology 2005, 15(1):116–120.
4.Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB: Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416(6881):636–640.
5.Kwok JC, Afshari F, Garcia-Alias G, Fawcett JW: Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC. Restorative neurology and neuroscience 2008, 26(2–3):131–145.
6.Garcia-Alias G, Barkhuysen S, Buckle M, Fawcett JW: Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. Nature neuroscience 2009, 12(9):1145–1151.
7.Crespo D, Asher RA, Lin R, Rhodes KE, Fawcett JW: How does chondroitinase promote functional recovery in the damaged CNS? Experimental neurology 2007, 206(2):159–171.
8.Jin Y, Zhang C, Ziemba KS, Goldstein GA, Sullivan PG, Smith GM: Directing dopaminergic fiber growth along a preformed molecular pathway from embryonic ventral mesencephalon transplants in the rat brain. Journal of neuroscience research 2011, 89(5):619–627.
9.Diaz-Martinez NE, Tamariz E, Diaz NF, Garcia-Pena CM, Varela-Echavarria A, Velasco I: Recovery from experimental parkinsonism by semaphorin-guided axonal growth of grafted dopamine neurons. Molecular therapy: the journal of the American Society of Gene Therapy 2013, 21(8):1579–1591.
10.Kauhausen JA, Thompson LH, Parish CL: Chondroitinase improves midbrain pathway reconstruction by transplanted dopamine progenitors in Parkinsonian mice. Molecular and cellular neurosciences 2015, 69:22–29.
11.Sekiya T, Holley MC, Hashido K, Ono K, Shimomura K, Horie RT, Hamaguchi K, Yoshida A, Sakamoto T, Ito J: Cells transplanted onto the surface of the glial scar reveal hidden potential for functional neural regeneration. Proceedings of the National Academy of Sciences of the United States of America 2015, 112(26):E3431–3440.
12.Moon LD, Asher RA, Rhodes KE, Fawcett JW: Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nature neuroscience 2001, 4(5):465–466.
13.Li HP, Homma A, Sango K, Kawamura K, Raisman G, Kawano H: Regeneration of nigrostriatal dopaminergic axons by degradation of chondroitin sulfate is accompanied by elimination of the fibrotic scar and glia limitans in the lesion site. Journal of neuroscience research 2007, 85(3):536–547.
14.Li HP, Komuta Y, Kimura-Kuroda J, van Kuppevelt TH, Kawano H: Roles of chondroitin sulfate and dermatan sulfate in the formation of a lesion scar and axonal regeneration after traumatic injury of the mouse brain. Journal of neurotrauma 2013, 30(5):413–425.
15.Lin R, Kwok JC, Crespo D, Fawcett JW: Chondroitinase ABC has a long-lasting effect on chondroitin sulphate glycosaminoglycan content in the injured rat brain. Journal of neurochemistry 2008, 104(2):400–408.
16.Ungerstedt U: 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European journal of pharmacology 1968, 5(1):107–110.
17.Duty S, Jenner P: Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology 2011, 164(4):1357–1391.
18.Yuan H, Sarre S, Ebinger G, Michotte Y: Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson’s disease. Journal of neuroscience methods 2005, 144(1):35–45.
19.Boix J, Padel T, Paul G: A partial lesion model of Parkinson’s disease in mice—characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behavioural brain research 2015, 284:196–206.
20.Heuer A, Smith GA, Lelos MJ, Lane EL, Dunnett SB: Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural brain research 2012, 228(1):30–43.
21.Iczkiewicz J, Broom L, Cooper JD, Wong AM, Rose S, Jenner P: The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. Journal of neurochemistry 2010, 114(6):1792–1804.
22.Betts MJ, O’Neill MJ, Duty S: Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson’s disease. British journal of pharmacology 2012, 166(8):2317–2330.
23.Penc SF, Pomahac B, Winkler T, Dorschner RA, Eriksson E, Herndon M, Gallo RL: Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor–2 function. The Journal of biological chemistry 1998, 273(43):28116–28121.
24.Deepa SS, Umehara Y, Higashiyama S, Itoh N, Sugahara K: Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues. The Journal of biological chemistry 2002, 277(46):43707–43716.
25.Nandini CD, Mikami T, Ohta M, Itoh N, Akiyama-Nambu F, Sugahara K: Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagfish. Neuritogenic and binding activities for growth factors and neurotrophic factors. The Journal of biological chemistry 2004, 279(49):50799–50809.
26.Winkler C, Sauer H, Lee CS, Bjorklund A: Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson’s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 1996, 16(22):7206–7215.
27.Voutilainen MH, Back S, Peranen J, Lindholm P, Raasmaja A, Mannisto PT, Saarma M, Tuominen RK: Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson’s disease. Experimental neurology 2011, 228(1):99–108.
28.Zachrisson O, Zhao M, Andersson A, Dannaeus K, Haggblad J, Isacson R, Nielsen E, Patrone C, Ronnholm H, Wikstrom L et al: Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson’s disease. J Parkinsons Dis 2011, 1(1):49–63.
29.Sleeman IJ, Boshoff EL, Duty S: Fibroblast growth factor–20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. Neuropharmacology 2012, 63(7):1268–1277.
30.Boshoff EL, Fletcher EJR, Duty S: Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner. Neuropharmacology 2018.
31.Barritt AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, McMahon SB, Bradbury EJ: Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 2006, 26(42):10856–10867.
32.Chen HH, Chang PC, Chen C, Chan MH: Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson’s disease. Pharmacol Rep 2018, 70(4):668–676.
33.Yu Z, Yang L, Yang Y, Chen S, Sun D, Xu H, Fan X: Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease. Front Cell Neurosci 2018, 12:324.
34.Eo H, Huh E, Sim Y, Oh MS: Ukgansan protects dopaminergic neurons from 6-hydroxydopamine neurotoxicity via activation of the nuclear factor (erythroid-derived 2)-like 2 factor signaling pathway. Neurochemistry international 2019, 122:208–215.
35.Huang WC, Kuo WC, Cherng JH, Hsu SH, Chen PR, Huang SH, Huang MC, Liu JC, Cheng H: Chondroitinase ABC promotes axonal re-growth and behavior recovery in spinal cord injury. Biochemical and biophysical research communications 2006, 349(3):963–968.
36.Curinga GM, Snow DM, Mashburn C, Kohler K, Thobaben R, Caggiano AO, Smith GM: Mammalian-produced chondroitinase AC mitigates axon inhibition by chondroitin sulfate proteoglycans. Journal of neurochemistry 2007, 102(1):275–288.
37.Bartus K, James ND, Didangelos A, Bosch KD, Verhaagen J, Yanez-Munoz RJ, Rogers JH, Schneider BL, Muir EM, Bradbury EJ: Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 2014, 34(14):4822–4836.
38.James ND, Shea J, Muir EM, Verhaagen J, Schneider BL, Bradbury EJ: Chondroitinase gene therapy improves upper limb function following cervical contusion injury. Experimental neurology 2015, 271:131–135.
39.Lee H, McKeon RJ, Bellamkonda RV: Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(8):3340–3345.
40.Mayer E, Brown VJ, Dunnett SB, Robbins TW: Striatal graft-associated recovery of a lesion-induced performance deficit in the rat requires learning to use the transplant. The European journal of neuroscience 1992, 4(2):119–126.
41.Fawcett JW: The extracellular matrix in plasticity and regeneration after CNS injury and neurodegenerative disease. Progress in brain research 2015, 218:213–226.
42.Wang D, Ichiyama RM, Zhao R, Andrews MR, Fawcett JW: Chondroitinase combined with rehabilitation promotes recovery of forelimb function in rats with chronic spinal cord injury. The Journal of neuroscience: the official journal of the Society for Neuroscience 2011, 31(25):9332–9344.
43.Chen W, Qiao D, Liu X, Shi K: Treadmill Exercise Improves Motor Dysfunction and Hyperactivity of the Corticostriatal Glutamatergic Pathway in Rats with 6-OHDA-Induced Parkinson’s Disease. Neural plasticity 2017, 2017:2583910.
44.da Costa RO, Gadelha-Filho CVJ, da Costa AEM, Feitosa ML, de Araujo DP, de Lucena JD, de Aquino PEA, Lima FAV, Neves KRT, de Barros Viana GS: The Treadmill Exercise Protects against Dopaminergic Neuron Loss and Brain Oxidative Stress in Parkinsonian Rats. Oxidative medicine and cellular longevity 2017, 2017:2138169.
45.Real CC, Garcia PC, Britto LRG: Treadmill Exercise Prevents Increase of Neuroinflammation Markers Involved in the Dopaminergic Damage of the 6-OHDA Parkinson’s Disease Model. Journal of molecular neuroscience: MN 2017, 63(1):36–49.
46.Shahaboddin ME, Khajeh K, Maleki M, Golestani A: Improvement of activity and stability of Chondroitinase ABC I by introducing an aromatic cluster at the surface of protein. Enzyme Microb Technol 2017, 105:38–44.
47.Burnside ER, De Winter F, Didangelos A, James ND, Andreica EC, Layard-Horsfall H, Muir EM, Verhaagen J, Bradbury EJ: Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury. Brain: a journal of neurology 2018, 141(8):2362–2381.
48.Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST: CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39(5):777–787.